|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MPP7 |
Gene summary for MPP7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MPP7 | Gene ID | 143098 |
| Gene name | membrane palmitoylated protein 7 | |
| Gene Alias | MPP7 | |
| Cytomap | 10p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0007043 | UniProtAcc | Q5T2T1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 143098 | MPP7 | LZE4T | Human | Esophagus | ESCC | 2.43e-03 | 7.18e-02 | 0.0811 |
| 143098 | MPP7 | LZE24T | Human | Esophagus | ESCC | 2.24e-10 | 5.02e-01 | 0.0596 |
| 143098 | MPP7 | P2T-E | Human | Esophagus | ESCC | 1.42e-03 | -9.30e-03 | 0.1177 |
| 143098 | MPP7 | P4T-E | Human | Esophagus | ESCC | 1.31e-07 | 7.31e-02 | 0.1323 |
| 143098 | MPP7 | P5T-E | Human | Esophagus | ESCC | 1.09e-04 | 3.38e-02 | 0.1327 |
| 143098 | MPP7 | P9T-E | Human | Esophagus | ESCC | 9.41e-07 | 8.59e-02 | 0.1131 |
| 143098 | MPP7 | P11T-E | Human | Esophagus | ESCC | 4.72e-06 | 3.19e-01 | 0.1426 |
| 143098 | MPP7 | P12T-E | Human | Esophagus | ESCC | 7.63e-04 | 3.61e-02 | 0.1122 |
| 143098 | MPP7 | P15T-E | Human | Esophagus | ESCC | 4.97e-05 | 1.12e-02 | 0.1149 |
| 143098 | MPP7 | P16T-E | Human | Esophagus | ESCC | 3.12e-08 | 1.12e-01 | 0.1153 |
| 143098 | MPP7 | P21T-E | Human | Esophagus | ESCC | 3.64e-10 | 1.01e-01 | 0.1617 |
| 143098 | MPP7 | P23T-E | Human | Esophagus | ESCC | 7.89e-03 | 4.88e-02 | 0.108 |
| 143098 | MPP7 | P26T-E | Human | Esophagus | ESCC | 2.63e-10 | 2.41e-01 | 0.1276 |
| 143098 | MPP7 | P27T-E | Human | Esophagus | ESCC | 5.85e-14 | 2.37e-01 | 0.1055 |
| 143098 | MPP7 | P28T-E | Human | Esophagus | ESCC | 3.30e-12 | 5.43e-02 | 0.1149 |
| 143098 | MPP7 | P30T-E | Human | Esophagus | ESCC | 3.54e-11 | 2.98e-01 | 0.137 |
| 143098 | MPP7 | P32T-E | Human | Esophagus | ESCC | 1.57e-04 | 8.43e-02 | 0.1666 |
| 143098 | MPP7 | P36T-E | Human | Esophagus | ESCC | 3.49e-08 | 9.89e-02 | 0.1187 |
| 143098 | MPP7 | P37T-E | Human | Esophagus | ESCC | 2.77e-09 | 1.87e-01 | 0.1371 |
| 143098 | MPP7 | P39T-E | Human | Esophagus | ESCC | 1.94e-03 | 2.50e-02 | 0.0894 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
| GO:003001018 | Esophagus | ESCC | establishment of cell polarity | 96/8552 | 143/18723 | 1.69e-07 | 2.67e-06 | 96 |
| GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
| GO:004521620 | Esophagus | ESCC | cell-cell junction organization | 114/8552 | 200/18723 | 8.04e-04 | 4.16e-03 | 114 |
| GO:004329718 | Esophagus | ESCC | apical junction assembly | 48/8552 | 78/18723 | 3.45e-03 | 1.41e-02 | 48 |
| GO:015010510 | Esophagus | ESCC | protein localization to cell-cell junction | 16/8552 | 21/18723 | 4.47e-03 | 1.76e-02 | 16 |
| GO:004325422 | Liver | HCC | regulation of protein-containing complex assembly | 264/7958 | 428/18723 | 5.47e-16 | 4.39e-14 | 264 |
| GO:003133412 | Liver | HCC | positive regulation of protein-containing complex assembly | 150/7958 | 237/18723 | 7.35e-11 | 2.63e-09 | 150 |
| GO:000716322 | Liver | HCC | establishment or maintenance of cell polarity | 133/7958 | 218/18723 | 2.48e-08 | 5.73e-07 | 133 |
| GO:003001022 | Liver | HCC | establishment of cell polarity | 82/7958 | 143/18723 | 2.38e-04 | 1.79e-03 | 82 |
| GO:015010511 | Liver | HCC | protein localization to cell-cell junction | 17/7958 | 21/18723 | 3.71e-04 | 2.56e-03 | 17 |
| GO:004521622 | Liver | HCC | cell-cell junction organization | 107/7958 | 200/18723 | 1.06e-03 | 6.11e-03 | 107 |
| GO:004329712 | Liver | HCC | apical junction assembly | 45/7958 | 78/18723 | 4.83e-03 | 2.03e-02 | 45 |
| GO:01201935 | Liver | HCC | tight junction organization | 45/7958 | 80/18723 | 9.02e-03 | 3.48e-02 | 45 |
| GO:01201925 | Liver | HCC | tight junction assembly | 42/7958 | 74/18723 | 9.32e-03 | 3.57e-02 | 42 |
| GO:000704312 | Liver | HCC | cell-cell junction assembly | 76/7958 | 146/18723 | 1.23e-02 | 4.47e-02 | 76 |
| GO:00071637 | Lung | IAC | establishment or maintenance of cell polarity | 61/2061 | 218/18723 | 3.10e-12 | 3.07e-09 | 61 |
| GO:00300107 | Lung | IAC | establishment of cell polarity | 46/2061 | 143/18723 | 7.70e-12 | 4.27e-09 | 46 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MPP7 | SNV | Missense_Mutation | c.665N>G | p.Glu222Gly | p.E222G | Q5T2T1 | protein_coding | tolerated(0.1) | possibly_damaging(0.77) | TCGA-A8-A08P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| MPP7 | SNV | Missense_Mutation | rs376428625 | c.378N>A | p.Met126Ile | p.M126I | Q5T2T1 | protein_coding | tolerated(0.45) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MPP7 | SNV | Missense_Mutation | c.298N>C | p.Ser100Pro | p.S100P | Q5T2T1 | protein_coding | deleterious(0.01) | possibly_damaging(0.707) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MPP7 | SNV | Missense_Mutation | novel | c.824C>G | p.Ala275Gly | p.A275G | Q5T2T1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MPP7 | SNV | Missense_Mutation | c.980N>C | p.Ser327Thr | p.S327T | Q5T2T1 | protein_coding | deleterious(0.05) | possibly_damaging(0.468) | TCGA-EW-A1P4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| MPP7 | SNV | Missense_Mutation | novel | c.163G>A | p.Glu55Lys | p.E55K | Q5T2T1 | protein_coding | tolerated(0.06) | probably_damaging(0.982) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| MPP7 | insertion | In_Frame_Ins | novel | c.1054_1055insTAGCATCTATCTTGTGCA | p.Pro352delinsLeuAlaSerIleLeuCysThr | p.P352delinsLASILCT | Q5T2T1 | protein_coding | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| MPP7 | SNV | Missense_Mutation | rs142463330 | c.241G>A | p.Glu81Lys | p.E81K | Q5T2T1 | protein_coding | deleterious(0) | possibly_damaging(0.597) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MPP7 | SNV | Missense_Mutation | novel | c.993N>C | p.Lys331Asn | p.K331N | Q5T2T1 | protein_coding | tolerated(0.1) | benign(0.131) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MPP7 | SNV | Missense_Mutation | rs775616676 | c.905N>A | p.Arg302Gln | p.R302Q | Q5T2T1 | protein_coding | tolerated(0.15) | benign(0.018) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |